Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 4/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7456502 | 0.89 | JMJD6 (0.55) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL4090687 | 0.88 | JMJD6 (0.51) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL4410496 | 0.88 | PIK3CA (0.52) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL29173821 | 0.87 | KDM4E (0.55) | JMJD6CA12CA1CA2CA7 | |
| SCHEMBL4087566 | 0.86 | JMJD6 (0.50) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL27925520 | 0.85 | GPR119 (0.53) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL31670763 | 0.83 | JMJD6 (0.50) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL363249 | 0.83 | JMJD6 (0.58) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL30171421 | 0.83 | JMJD6 (0.76) | JMJD6PIK3CACA12CA1CA2 | |
| SCHEMBL14480077 | 0.83 | CREBBP (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4482839-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-119110800-A | Modulators of interferon gene stimulating factor (STING), compositions and methods | 健道生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023158862-A2 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | GENZYME CORPORATION | 2017-10-05 | — | — | US | disclosed |
| EP-3188729-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | Genzyme Corporation (US) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016036796-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) INHIBITORS | GENZYME CORPORATION (US) | 2016-03-10 | — | — | WO | disclosed |
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-7354933-B2 | Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate | AVENTIS PHARMA SA (FR) | 2008-04-08 | — | — | US | disclosed |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281641-A1 | CYCLIC UREA COMPOUNDS AS TROPOMYOSIN-RELATED KINASE (TRK) iNHIBITORS | NGF, NTRK1, TK1 | JMJD6 2127/4885PIK3CA 1502/4885CA12 4390/4885 |
| US-20250171461-A1 | STIMULATOR OF INTERFERON GENES (STING) MODULATORS, AND COMPOSITIONS AND METHODS THEREOF | STING1, IRF3, CGAS | JMJD6 3243/4885PIK3CA 926/4885CA12 4808/4885 |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKG1, PRKACA, CMPK1 | JMJD6 2087/4885PIK3CA 211/4885CA12 4171/4885 |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | PRKG1, PRKACA, PRKCA | JMJD6 2243/4885PIK3CA 160/4885CA12 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.